Daclizumab

General information

Daclizumab, a humanized antibody directed against the alfa chain of the interleukin-2 receptor, has been used for initial immunosuppression in transplant patients. In a phase III trial in 275 patients who received ciclosporin, glucocorticoids, and daclizumab or placebo, there were no specific adverse effects associated with daclizumab [ ]. In particular, the cytokine-release syndrome did not occur, and there was no difference in the incidence of fungal or cytomegalovirus infections between the two groups.

Drug studies